Immuno-Oncology | Specialty

Dr. Plimack on Second-Line Checkpoint Inhibitors in Bladder Cancer

December 12th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the approved checkpoint inhibitors for the second-line treatment of patients with bladder cancer.

Atezolizumab Plus Bevacizumab Meets Primary Endpoint for PFS in Advanced or Metastatic mRCC

December 12th 2017

In top-line results from the phase III IMmotion151 trial, the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) was associated with a statistically significant reduction in the risk for death or progression in patients with PD-L1

Dr. McKay Discusses Immunotherapy Trials in RCC

December 12th 2017

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy trials in renal cell carcinoma.

FDA Grants Priority Review to Pembrolizumab for Relapsed/Refractory PMBCL

December 11th 2017

The FDA has granted a priority review to a supplemental biologics license application for pembrolizumab (Keytruda) as a treatment for adult and pediatric patients with relapsed/refractory primary mediastinal large B-cell lymphoma.

Abemaciclib/Pembrolizumab Combo Shows Early Promise for HR+/HER2- Breast Cancer

December 9th 2017

The combination of abemaciclib and pembrolizumab showed preliminary signs of activity without additive toxicity for patients with pretreated HR-positive, HER2-negative metastatic breast cancer.

Dr. Zhang Discusses the KEYNOTE-564 Trial in RCC

December 8th 2017

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the KEYNOTE-564 trial in renal cell carcinoma.

Frontline Atezolizumab Regimen Improves PFS in NSCLC

December 7th 2017

Treatment with the combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel delayed progression or death by 38% compared with bevacizumab and chemotherapy alone for patients with advanced non-squamous non–small cell lung cancer.

FDA Lifts Holds on 2 Nivolumab Myeloma Trials

December 6th 2017

The FDA has lifted partial clinical holds placed on the phase I CheckMate-039 and phase II CA204142 trials exploring nivolumab-based regimens in patients with relapsed/refractory multiple myeloma.

Simon Says Immunotherapy Combo Regimens on Horizon in NSCLC

December 4th 2017

George R. Simon, MD, discusses the advancements being made with immunotherapy for the treatment of NSCLC.

Nivolumab Improves Survival in Pretreated Chinese NSCLC Patients

December 1st 2017

Nivolumab improved survival versus docetaxel in a predominantly Chinese population of patients with pretreated advanced or metastatic non-small cell lung cancer.

Checkpoint Inhibitors Hold Promise for BCG-Unresponsive NMIBC

December 1st 2017

The established efficacy of single-agent checkpoint inhibition for metastatic urothelial carcinoma along with molecule expression analyses suggests that PD-1/PD-L1 inhibition could hold promise for patients with non-muscle invasive bladder cancer, particularly those unresponsive to Bacillus Calmette-Guérin.

Immunotherapy Combinations on the Rise for RCC

November 30th 2017

The combination of PD-1 or PD-L1 inhibitors with existing frontline therapies could represent a superior approach for some treatment-naïve patients with renal cell carcinoma.

Plethora of Ongoing Trials Explore Immunotherapy Combinations for Bladder Cancer

November 30th 2017

Stemming from the wave of checkpoint inhibitor approvals, multiple trials have begun evaluating immunotherapies in combination with other agents for the treatment of patients with advanced bladder cancer.

Future of Bladder Cancer Care to Include Immunotherapy Combos

November 29th 2017

Petros Grivas, MD, shares insight on the value of combining immunotherapy regimens in the treatment of patients with urothelial carcinoma.

Immunotherapy to Have Emerging Role in Squamous Cell Lung Cancer

November 22nd 2017

George R. Blumenschein, MD, discusses the current treatment landscape for patients with squamous cell lung cancer.

Dr. Heinzerling on the Development of New Treatments in Early-Stage Lung Cancer

November 22nd 2017

Josh H. Heinzerling, MD, Department of Radiation Oncology, Levine Cancer Institute, discusses the development of new treatment regimens for patients with early-stage lung cancer.

Durvalumab Data Published in NEJM as FDA Weighs NSCLC Approval

November 21st 2017

The FDA granted a priority review to durvalumab in October for the treatment of patients with stage III, unresectable non-small cell lung cancer whose disease has not progressed following platinum-based chemoradiation.

Expert Discusses Promise of Checkpoint Inhibitors in Ovarian Cancer

November 21st 2017

Jonathan Ledermann, MD, discusses the promise of immunotherapy in ovarian cancer and emphasized the importance of participation in clinical trials.

Dr. Inman on Immunotherapy Combinations in Bladder Cancer

November 21st 2017

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses novel immunotherapy combinations for patients with bladder cancer.

Atezolizumab/Bevacizumab Combo Improves PFS for Untreated Advanced NSCLC

November 20th 2017

The addition of atezolizumab to bevacizumab, carboplatin, and paclitaxel delayed progression or death compared with bevacizumab and chemotherapy alone for patients with advanced non-squamous non–small cell lung cancer.